Organic Acids
Medchemexpress LLC SLB1122168 formic | C23H37N3O3 | 5 MG
SLB1122168 formic is a potent Spns2-mediated S1P release inhibitor with an IC50 of 94 nM. This compound is for research use only. In vivo, it causes a dose-dependent decrease in circulating lymphocytes. In rats, at 10 mg/kg, SLB1122168 reaches a maximum concentration of 4 μM at 2 hours post-dose, maintains levels at ≥1 μM for 24 hours, and has a half-life of 8 hours.
- Potent Spns2-mediated S1P release inhibitor
- IC50 of 94 nM
- Causes a dose-dependent decrease in circulating lymphocytes
- Suitable for research applications
- Demonstrates sustained in vivo activity with levels ≥1 μM for 24 hours
- Half-life of 8 hours in rats
Medchemexpress LLC SLB1122168 formic | 2999629-17-1 | C23H37N3O3 | 50 MG
SLB1122168 formic is a potent Spns2-mediated S1P release inhibitor with an IC50 of 94 nM. It leads to a dose-dependent decrease in circulating lymphocytes, and in rats, it achieves a maximum concentration of 4 μM at 2 hours post-dose, maintaining levels ≥1 μM for 24 hours with a half-life of 8 hours.
- Potent Spns2-mediated S1P release inhibitor with an IC50 of 94 nM
- Induces a dose-dependent decrease in circulating lymphocytes
- Relevant for research in respiratory disease, inflammation or immune system disease, pulmonary disease, and lung fibrosis
- Acts on inflammation/immunology signaling pathways, GPCR/G protein, and LPL receptor
Medchemexpress LLC SLB1122168 formic | C23H37N3O3 | 10 MM * 1 ML
SLB1122168 formic is a potent Spns2-mediated S1P release inhibitor with an IC50 of 94 nM. It is intended for research use only and available in various forms, including solid and as a 10 mM * 1 mL solution in DMSO.
- Potent Spns2-mediated S1P release inhibitor with an IC50 of 94 nM
- Intended for research use only
- Purity of 99.91%
- Molecular weight of 403.56
- Appears as an off-white to light yellow solid
- Soluble in DMSO at 100 mg/mL (247.79 mM)
- Induces a dose-dependent decrease in circulating lymphocytes in vivo
- Achieves a maximum concentration of 4 μM in rats at 2 hours post-dose with a half-life of 8 hours
- Related to respiratory, inflammatory, and pulmonary diseases, and lung fibrosis
- Affects inflammation/immunology, GPCR/G protein, and LPL receptor signaling pathways